Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Shares Outstanding (Weighted Average) (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Shares Outstanding (Weighted Average) data on record, last reported at $13.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.21% year-over-year to $13.8 million; the TTM value through Oct 2025 reached $13.8 million, up 1.21%, while the annual FY2025 figure was $13.7 million, 0.83% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $13.8 million in Q4 2025 per CSBR's latest filing, roughly flat from $13.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $13.8 million in Q3 2025 and bottomed at $13.1 million in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $13.5 million, with a median of $13.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 13.78% in 2021, then decreased 0.12% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $13.4 million in 2021, then increased by 0.69% to $13.5 million in 2022, then rose by 0.06% to $13.5 million in 2023, then increased by 0.47% to $13.6 million in 2024, then increased by 1.21% to $13.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $13.8 million in Q4 2025, $13.8 million in Q3 2025, and $13.7 million in Q2 2025.